Published in J Biol Chem on November 01, 2013
The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J Pharmacol Exp Ther (2014) 1.05
Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery. Mol Endocrinol (2014) 1.04
Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism. Mol Pharmacol (2015) 1.01
Does the kappa opioid receptor system contribute to pain aversion? Front Pharmacol (2014) 0.92
Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A. Br J Pharmacol (2014) 0.89
A novel method for analyzing extremely biased agonism at G protein-coupled receptors. Mol Pharmacol (2015) 0.87
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2. J Med Chem (2016) 0.87
Supersensitive Kappa Opioid Receptors Promotes Ethanol Withdrawal-Related Behaviors and Reduce Dopamine Signaling in the Nucleus Accumbens. Int J Neuropsychopharmacol (2016) 0.84
Identification of the Kappa-Opioid Receptor as a Therapeutic Target for Oligodendrocyte Remyelination. J Neurosci (2016) 0.81
Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias. ACS Chem Neurosci (2015) 0.81
Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus. Neuropharmacology (2015) 0.80
Quantitative Signaling and Structure-Activity Analyses Demonstrate Functional Selectivity at the Nociceptin/Orphanin FQ Opioid Receptor. Mol Pharmacol (2015) 0.80
Intrinsic relative activities of κ opioid agonists in activating Gα proteins and internalizing receptor: Differences between human and mouse receptors. Eur J Pharmacol (2015) 0.80
Effects of kappa opioid receptors on conditioned place aversion and social interaction in males and females. Behav Brain Res (2014) 0.79
Approaches to Assess Functional Selectivity in GPCRs: Evaluating G Protein Signaling in an Endogenous Environment. Methods Mol Biol (2015) 0.78
Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects. J Med Chem (2014) 0.78
Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Front Pharmacol (2015) 0.78
Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability. J Med Chem (2016) 0.78
Gaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessors. Br J Pharmacol (2015) 0.77
Opioid receptors: Structural and mechanistic insights into pharmacology and signaling. Eur J Pharmacol (2015) 0.77
Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology. Biomol Ther (Seoul) (2017) 0.77
Selective κ receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice. Br J Pharmacol (2017) 0.76
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal (2016) 0.76
Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design. Sci Rep (2016) 0.76
Potency enhancement of the κ-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif. Bioorg Med Chem (2014) 0.76
Current approaches for the discovery of drugs that deter substance and drug abuse. Expert Opin Drug Discov (2014) 0.75
Molecular switches of the κ opioid receptor triggered by 6'-GNTI and 5'-GNTI. Sci Rep (2016) 0.75
Factors influencing biased agonism in recombinant cells expressing the human α1A -adrenoceptor. Br J Pharmacol (2017) 0.75
Discovery of G Protein-Biased EP2 Receptor Agonists. ACS Med Chem Lett (2016) 0.75
Synthesis of Kappa Opioid Antagonists Based On Pyrrolo[1,2-α]quinoxalinones Using an N-Arylation/Condensation/Oxidation Reaction Sequence. J Org Chem (2016) 0.75
Endogenous opioid system: a promising target for future smoking cessation medications. Psychopharmacology (Berl) (2017) 0.75
Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders. PLoS One (2017) 0.75
The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling. Pharmacol Rev (2017) 0.75
Transduction of receptor signals by beta-arrestins. Science (2005) 9.87
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci (1983) 6.89
Structure of the human κ-opioid receptor in complex with JDTic. Nature (2012) 5.18
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A (2002) 4.34
Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science (1999) 4.04
Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science (1982) 3.80
Psychotomimesis mediated by kappa opiate receptors. Science (1986) 3.60
The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci (2008) 3.54
Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature (2000) 3.42
Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov (2012) 3.30
Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol (2011) 3.15
A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem (1997) 3.12
Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem (2004) 3.07
β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci (2011) 3.02
U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. J Pharmacol Exp Ther (1983) 2.65
Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. J Neurosci (2007) 2.51
Dynorphin, stress, and depression. Brain Res (2009) 2.45
Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol (1994) 2.33
The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci U S A (2003) 2.29
Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem (2006) 1.97
A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci (2011) 1.93
Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl) (2010) 1.90
[3H]U-69593 a highly selective ligand for the opioid kappa receptor. Eur J Pharmacol (1985) 1.77
Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. J Med Chem (2001) 1.54
Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes. J Biol Chem (2005) 1.46
Prolonged kappa opioid receptor phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic tolerance. J Biol Chem (2003) 1.45
Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci Res (1995) 1.36
Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity. J Biomol Screen (2009) 1.30
Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J Pharmacol Exp Ther (1987) 1.25
5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. Eur J Pharmacol (2000) 1.23
Dynorphin A decreases voltage-dependent calcium conductance of mouse dorsal root ganglion neurones. J Physiol (1986) 1.22
Real-time visualization of the cellular redistribution of G protein-coupled receptor kinase 2 and beta-arrestin 2 during homologous desensitization of the substance P receptor. J Biol Chem (1999) 1.19
Multiple opiate receptors: [3H]ethylketocyclazocine receptor binding and ketocyclazocine analgesia. Proc Natl Acad Sci U S A (1980) 1.19
Repeated swim stress induces kappa opioid-mediated activation of extracellular signal-regulated kinase 1/2. Neuroreport (2008) 1.17
Mu opioid receptor regulation and opiate responsiveness. AAPS J (2005) 1.16
Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther (2008) 1.15
Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade. J Neurochem (2000) 1.12
The therapeutic potential of κ-opioids for treatment of pain and addiction. Neuropsychopharmacology (2011) 1.11
14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects. J Med Chem (2012) 1.11
6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment. J Biol Chem (2012) 1.09
Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons. J Biol Chem (2013) 1.08
Synthesis of N-alkyl-octahydroisoquinolin-1-one-8-carboxamide libraries using a tandem Diels-Alder/acylation sequence. J Comb Chem (2007) 1.05
Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways. J Neurochem (2008) 1.05
Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action. J Pharmacol Exp Ther (1989) 1.01
Quantification of functional selectivity at the human α(1A)-adrenoceptor. Mol Pharmacol (2010) 0.98
Impedance-based cellular assay technologies: recent advances, future promise. Curr Opin Pharmacol (2007) 0.94
Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6. Drug Alcohol Depend (2009) 0.94
Seeking Ligand Bias: Assessing GPCR Coupling to Beta-Arrestins for Drug Discovery. Drug Discov Today Technol (2010) 0.90
Signaling in time and space: G protein-coupled receptors and mitogen-activated protein kinases. Assay Drug Dev Technol (2003) 0.90
Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. ACS Chem Neurosci (2012) 0.89
Recent developments in the study of opioid receptors. Mol Pharmacol (2012) 0.89
Properties of a kappa-opioid receptor expressed in CHO cells: interaction with multiple G-proteins is not specific for any individual G alpha subunit and is similar to that of other opioid receptors. Brain Res Mol Brain Res (1995) 0.88
N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: a Novel Class of Selective, Nonbasic, Nitrogen-Containing κ-Opioid Receptor Ligands. ACS Med Chem Lett (2010) 0.88
Cannabinoid signaling in rat cerebellar granule cells: G-protein activation, inhibition of glutamate release and endogenous cannabinoids. Neuropharmacology (2004) 0.86
Rapid method for the estimation of octanol/water partition coefficient (log P(oct)) from gradient RP-HPLC retention and a hydrogen bond acidity term (zetaalpha(2)(H)). Curr Med Chem (2001) 0.85
The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line is coupled to adenylyl cyclase through a pertussis toxin-sensitive guanine nucleotide-binding regulatory protein. J Pharmacol Exp Ther (1993) 0.82
Role of L-type Ca(2+) channels in pertussis toxin induced antagonism of U50,488H analgesia and hypothermia. Brain Res (2002) 0.81
Development of a high-throughput screening-compatible cell-based functional assay to identify small molecule probes of the galanin 3 receptor (GalR3). Assay Drug Dev Technol (2013) 0.79
kappa-Opioid receptor activates an inwardly rectifying K+ channel by a G protein-linked mechanism: coexpression in Xenopus oocytes. Mol Pharmacol (1995) 0.79
Calcitonin reverts pertussis toxin blockade of the opioid analgesia in mice. Neurosci Lett (1999) 0.78
Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci (2004) 4.44
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature (2011) 4.23
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci U S A (2011) 3.20
Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature (2012) 2.67
Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. J Med Chem (2005) 2.13
Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron (2003) 2.03
Insular hypocretin transmission regulates nicotine reward. Proc Natl Acad Sci U S A (2008) 1.94
Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol (2002) 1.93
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther (2009) 1.88
Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther (2005) 1.79
Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer. Mol Pharmacol (2005) 1.73
Small-molecule proteostasis regulators for protein conformational diseases. Nat Chem Biol (2011) 1.64
Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev (2011) 1.61
A facile method for the preparation of deuterium labeled salvinorin A: synthesis of [2,2,2-2H3]-salvinorin A. Bioorg Med Chem Lett (2004) 1.60
Synthetic studies of neoclerodane diterpenoids from Salvia splendens and evaluation of Opioid Receptor affinity. Tetrahedron (2008) 1.53
Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A (2008) 1.51
Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology (Berl) (2014) 1.48
Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis. Cancer Res (2013) 1.46
Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain. Nat Chem (2011) 1.44
Synthesis of salvinorin A analogues as opioid receptor probes. J Nat Prod (2006) 1.39
Facile C-N cleavage in a series of bridged lactams. J Am Chem Soc (2005) 1.37
Small molecule activators of TRPML3. Chem Biol (2010) 1.37
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A. J Nat Prod (2006) 1.36
Reactive oxygen and targeted antioxidant administration in endothelial cell mitochondria. J Biol Chem (2006) 1.35
Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci U S A (2013) 1.34
Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol (2012) 1.32
Revisiting a classic approach to the Aspidosperma alkaloids: an intramolecular Schmidt reaction mediated synthesis of (+)-aspidospermidine. J Org Chem (2005) 1.31
The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology (2010) 1.30
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ring. Bioorg Med Chem Lett (2006) 1.29
Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A (2003) 1.27
Ligand-binding pocket shape differences between sphingosine 1-phosphate (S1P) receptors S1P1 and S1P3 determine efficiency of chemical probe identification by ultrahigh-throughput screening. ACS Chem Biol (2008) 1.26
Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev (2011) 1.26
Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. ChemMedChem (2013) 1.25
A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse (2007) 1.24
Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem (2013) 1.24
Salvinicins A and B, new neoclerodane diterpenes from Salvia divinorum. Org Lett (2005) 1.23
Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist. ACS Chem Biol (2010) 1.22
Salvinorin A: allosteric interactions at the mu-opioid receptor. J Pharmacol Exp Ther (2006) 1.21
Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo. J Neurosci (2010) 1.21
Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend (2010) 1.20
Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol (2007) 1.20
Identification of Drosophila neuropeptide receptors by G protein-coupled receptors-beta-arrestin2 interactions. J Biol Chem (2003) 1.20
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. J Med Chem (2007) 1.18
Cation-pi control of regiochemistry of intramolecular schmidt reactions en route to bridged bicyclic lactams. J Am Chem Soc (2007) 1.18
Mu opioid receptor regulation and opiate responsiveness. AAPS J (2005) 1.16
Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther (2008) 1.15
A combined intramolecular Diels-Alder/intramolecular schmidt reaction: formal synthesis of (+/-)-stenine. Angew Chem Int Ed Engl (2002) 1.14
Domino reactions that combine an azido-Schmidt ring expansion with the Diels-Alder reaction. Org Lett (2004) 1.14
Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORα and RORγ. ACS Chem Biol (2010) 1.14
Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates. Synapse (2005) 1.13
Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation. J Biol Chem (2011) 1.13
Potent, selective and cell penetrant inhibitors of SF-1 by functional ultra-high-throughput screening. Mol Pharmacol (2008) 1.12
Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. J Pharmacol Exp Ther (2006) 1.12
Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther (2008) 1.12
Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon. Am J Physiol Gastrointest Liver Physiol (2009) 1.12
R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry (2012) 1.12
Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol Biochem Behav (2009) 1.11
Syntheses of the Stemona alkaloids (+/-)-stenine, (+/-)-neostenine, and (+/-)-13-epineostenine using a stereodivergent Diels-Alder/azido-Schmidt reaction. J Am Chem Soc (2008) 1.10
Anxious behavior and fenfluramine-induced prolactin secretion in young rhesus macaques with different alleles of the serotonin reuptake transporter polymorphism (5HTTLPR). Behav Genet (2004) 1.10
Genetic regulation of behavioral and neuronal responses to fluoxetine. Neuropsychopharmacology (2007) 1.10
A tandem Prins/Schmidt reaction approach to marine alkaloids: formal and total syntheses of lepadiformines A and C. Org Lett (2010) 1.09
An expeditious total synthesis of (+/-)-stenine. J Am Chem Soc (2005) 1.08
Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons. J Biol Chem (2013) 1.08
Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse. J Pharmacol Exp Ther (2010) 1.08
Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J Med Chem (2008) 1.07
Regioselective single and double conjugate additions to substituted cyclohexa-2,5-dienone monoacetals. Org Lett (2005) 1.07
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position. Bioorg Med Chem Lett (2007) 1.07
A fluorescence-based thiol quantification assay for ultra-high-throughput screening for inhibitors of coenzyme A production. Assay Drug Dev Technol (2008) 1.05
Medium-bridged lactams: a new class of non-planar amides. Org Biomol Chem (2010) 1.05
Synthesis of N-alkyl-octahydroisoquinolin-1-one-8-carboxamide libraries using a tandem Diels-Alder/acylation sequence. J Comb Chem (2007) 1.05
Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. J Med Chem (2010) 1.05
Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways. J Neurochem (2008) 1.05
Minor withanolides of Physalis longifolia: structure and cytotoxicity. Chem Pharm Bull (Tokyo) (2012) 1.04
Eliciting renal failure in mosquitoes with a small-molecule inhibitor of inward-rectifying potassium channels. PLoS One (2013) 1.04
Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem (2008) 1.03
Kappa opioids and the modulation of pain. Psychopharmacology (Berl) (2010) 1.03
High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem (2008) 1.03
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues. Bioorg Med Chem Lett (2011) 1.03
S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis. Mol Pharmacol (2011) 1.03
Development of an intact cell reporter gene beta-lactamase assay for G protein-coupled receptors for high-throughput screening. Anal Biochem (2003) 1.02
Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries. Bioorg Med Chem (2009) 1.02
Apparent loss-of-function mutant GPCRs revealed as constitutively desensitized receptors. Biochemistry (2002) 1.02
Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.01
Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays. Nucleic Acids Res (2012) 1.00
A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists. J Med Chem (2004) 1.00
Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker. Bioorg Med Chem (2013) 1.00
Uptake, distribution and diffusivity of reactive fluorophores in cells: implications toward target identification. Mol Pharm (2010) 1.00
Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend (2011) 1.00